Roche Receives FDA Approval for Lunsumio in Relapsed or Refractory Follicular Lymphoma

Roche today announced that the FDA has granted accelerated approval to Lunsumio (mosunetuzumab-axgb) for adults with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies. Lunsumio is a CD20xCD3 bispecific antibody that redirects T cells to kill CD20-positive B-cell lymphoma cells. In the GO29781 trial, Lunsumio demonstrated a complete response rate of 60% in patients with relapsed or refractory FL. The fixed-duration treatment course of 8 cycles is a unique feature that allows patients to stop treatment after completing the course. This approval provides a new treatment option for patients with relapsed or refractory FL.